期刊文献+

不同心肌损伤生化标志物检验的临床分析 被引量:3

下载PDF
导出
摘要 目的:研究分析不同心肌损伤生化标志物检验的临床资料为临床诊断及治疗提供科学依据。方法:回顾性分析2017年1月1日至2017年12月31日清远市人民医院收治的200例心肌梗死病人的临床资料(Ⅰ组),另选取同一时期到本院进行健康体检的200例受检者的临床资料作为对比(Ⅱ组),对比两组受检者五项生化标志物的检验结果。结果:Ⅰ组受检者肌酸激酶同工酶(CK–MB)、心肌肌钙蛋白Ⅰ(c Tn I)、肌红蛋白(Mb)、血同型半胱氨酸(Hcy)及B型利钠肽(BNP)检验结果比Ⅱ组受检者高,组间比较,差异具有统计学意义(P<0.05)。经检验后发现CK–MB的灵敏度为84.7%,c Tn I灵敏度为100.0%,Mb灵敏度为70.7%,Hcy灵敏度为72.1%,BNP灵敏度为100.0%。结论:不同心肌损伤生化标志物均可以作为诊断心肌损伤的标准,CK–MB、c Tn I、Mb、Hcy及BNP起到了互补的作用,更精准地提高心肌损伤的检出率,为临床的诊断及治疗提供了科学的数据,在诊断心肌损伤方面有着重要的应用价值。
作者 朱杏谊
机构地区 清远市人民医院
出处 《深圳中西医结合杂志》 2018年第11期65-67,共3页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献6

二级参考文献46

  • 1张星利.对比不同心肌损伤生化标记物检验的临床意义[J].临床研究,2015,23(5):21-21. 被引量:3
  • 2Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study [J]. Eur Heart J, 2006, 27(3): 330-337.
  • 3Pfisterer M, Buser P, Rickli H, et al. BNP-gnided vs symptom-gnided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial [J]. JAMA, 2009, 301(4): 383-392.
  • 4Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial [J]. J Am Coil Cardiol, 2009, 55(1): 53-60.
  • 5Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart failure morbidity and mortality?) study [I]. j Am Coil Cardiol, 2010 56(25): 2090-2100.
  • 6Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death [J]. J Am Coil Cardiol, 2009, 53(19): 1783-17 90.
  • 7Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial [J]. J Am Coil Cardiol, 2010, 55(19): 2062-2076.
  • 8McMurray J J, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2012, 33(14): 1787-1847.
  • 9Yanavitski M, Givertz MM. Novel biomarkers in acute heart failure [J]. Curr Heart Fail Rep, 2011, 8(3): 206-211.
  • 10Dieplinger B, Gegenhuber A, Kaar G, et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department [J]. Clin Biochem, 2010, 43(9):71 4-719.

共引文献35

同被引文献17

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部